Zealand Pharma

Earnings Release • Jul 29, 2016

-- Royalty revenue of DKK 6.4 million / €0.9 million in Q2 2016 on Sanofi’s
sales of Lyxumia® (lixisenatide outside the U.S.)
-- Recently, the U.S. FDA approved lixisenatide as Adlyxin(TM) to treat type 2
diabetes, and commercial launch by Sanofi in the U.S. is expected later in
H2 2016

Copenhagen, 29 July 2016 – Zealand Pharma (Zealand), a biotechnology company,
reports royalty revenue from Sanofi’s global sales of Lyxumia® (lixisenatide
outside the U.S.) of DKK 6.4 million / €0.9 million for the period from 1 April
to 30 June 2016. For the first half of 2016, royalty revenue amounted to DKK
12.9 million / €1.7 million, a decrease of 3% compared to the same period in
2015. In its Q2 2016 earnings release today, Sanofi reported that sales of
Lyxumia® were stable in H1 2016 versus the same period last year, measured at
constant exchange rates.

Lixisenatide is a once-daily prandial GLP-1 receptor agonist for the treatment
of patients with type 2 diabetes and was invented by Zealand. Global
development and commercialization rights are licensed to Sanofi. Lixisenatide
is approved under the proprietary name, Lyxumia®, in more than 60 countries
outside the U.S. and marketed by Sanofi in over 40 of these, including most EU
countries (excluding France and Germany), Japan, Brazil, Mexico and India.

On 27 July 2016, lixisenatide was approved by the U.S. Food and Drug
Administration (FDA) under the name of Adlyxin(TM). U.S. commercial launch by
Sanofi is expected later in H2 2016.

Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide
insulin glargine 100 Units/mL (Lantus®), its worldwide most-prescribed basal
insulin, for the treatment of type 2 diabetes. iGlarLixi is undergoing
regulatory review in both the U.S. and Europe. On May 25, an Advisory Committee
of the FDA recommended the approval of iGlarLixi and a regulatory decision by
the FDA is expected in August 2016. In Europe, a regulatory decision is
expected in Q1 2017.

                                  ?????

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer, Tel: +45 51 67 61
28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President, Investor Relations and
Communications, Tel: +45 50 60 36 89, email: hlh@zealandpharma.com